|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data indicated that PPAR-<i>γ</i> may have the therapeutic potential in atherosclerosis via the transcriptional regulation of miR-590-5p in endothelial cells.
|
31354796 |
2019 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PPARγ and PPARα belong to a receptor family of ligand-activated transcription factors involved in the regulation of inflammation, cellular glucose uptake, protection against atherosclerosis and endothelial cell function.
|
30697628 |
2019 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therapeutic advantages might derive from the use of compounds selective for nuclear receptors targeting PPARs rather than LXRs regulating macrophage lipid metabolism and macrophage mediated inflammation, by favoring the expression of MerTK, which mediates an immunoregulatory action with a reduction in inflammation and in atherosclerosis.
|
31191323 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, EEDT played a key role in anti-inflammation and preventing lipid deposition in macrophages of atherosclerosis via suppressing NF-κB signaling and triggering PPARα/ABCA1 signaling pathway.
|
31181336 |
2019 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The abnormal expression of PPAR-α is closely related to atherosclerosis, indicating that the correlation between PPAR-α methylation levels in peripheral blood and atherosclerosis of NAFLD patients with DM can provide a new direction of diagnosis and treatment.
|
29456675 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that NXT could retard atherosclerosis by inhibiting foam cell formation through reducing ox-LDL uptake and enhancing cholesterol efflux and above beneficial effects are partly mediated through PPARα pathway.
|
30734676 |
2018 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A HFD induced atherosclerosis formation and lipid metabolism disorders as well as reduced autophagy expression in the vessel wall of ApoE-knockout mice, but GTP treatment alleviated the lipid metabolism disorders, decreased the oxLDL levels in serum, and increased the mRNA and protein expressions of hepatic PPARα and autophagy markers (LC3, Beclin1 and p62) in the vessel wall of ApoE-knockout mice.
|
28777810 |
2017 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PPARx03B3; and PPARα belong to a receptor family of ligand-activated transcription factors involved in the regulation of inflammation, cellular glucose uptake, protection against atherosclerosis and endothelial cell function.
|
26671025 |
2016 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, AR ameliorated atherosclerosis via the regulation of hepatic lipid metabolism, and AR also contributed to the activation of PPAR-alpha, APOA1, APOA2 and APOC3.
|
25979856 |
2015 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results provide evidence that multiple PPARα/δ/γ gene polymorphisms are individually associated with increased LDL-C, and that interactions, among these alleles result in additional increased risk suggesting that PPAR genes may contribute substantially to the risk of cardiovascular diseases and atherosclerosis.
|
26098621 |
2015 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to analyze, using homo- and heterozygous PPARα-deficient mice, the consequences of quantitative variations of PPARα gene levels and their response to the synthetic PPARα agonist fenofibrate on NASH and atherosclerosis in apoE2-KI mice.
|
21474829 |
2011 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
|
19220285 |
2009 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the potential effect modification of PPARA genetic variation on the association between PUFA intake, specifically n-6 and long-chain n-3 fatty acid intakes, and multiple lipid measures in the large biethnic Atherosclerosis Risk in Communities (ARIC) Study.
|
18541586 |
2008 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
|
17261671 |
2007 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor alpha (PPARalpha) ligands are medications used to treat hyperlipidaemia and atherosclerosis.
|
17888025 |
2007 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
|
17909121 |
2007 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Because PPARalpha and gamma modulate macrophage gene expression and cellular function, it has been suggested that their ligands may modulate atherosclerosis development via direct effects on macrophages.
|
15994444 |
2005 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the PPARalpha/p16 pathway may be a potential pharmacological target for the prevention of cardiovascular occlusive complications of atherosclerosis.
|
16239970 |
2005 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Like the PPARgamma agonist, a PPARalpha-specific agonist strongly inhibited atherosclerosis, whereas a PPARbeta-specific agonist failed to inhibit lesion formation.
|
15578089 |
2004 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effects of the polymorphism of PPARalpha on plasma lipids and atherosclerosis development have been until now contradictory.
|
15199365 |
2004 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fibrates are ligands for peroxisome proliferator-activated receptor alpha (PPARalpha) that modulate risk factors related to atherosclerosis by acting at both systemic and vascular levels.
|
12377786 |
2002 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PPARalpha gene affects progression of atherosclerosis and risk of IHD.
|
11914252 |
2002 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator activated receptor alpha (PPARalpha) regulates genes involved in lipid metabolism, haemostasis and inflammation, in response to fatty acids and fibrates, making it a candidate gene for risk of dyslipidaemia, atherosclerosis and coronary artery disease.
|
10855543 |
2000 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.
|
10431661 |
1999 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously reported that peroxisome proliferator-activated receptor alpha (PPARalpha) ligands (fibrates) lower elevated plasma concentrations of IL-6 in patients with atherosclerosis and inhibit IL-1-stimulated IL-6 secretion by human aortic smooth muscle cells (SMC).
|
10542237 |
1999 |